CURI saw its Momentum Indicator move below the 0 level on March 31, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In of the 90 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for CURI moved out of overbought territory on March 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for CURI turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CURI broke above its upper Bollinger Band on March 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CURI entered a downward trend on March 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
CURI moved above its 50-day moving average on March 12, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CURI advanced for three days, in of 203 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CURI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CURI's P/B Ratio (2.720) is slightly higher than the industry average of (1.002). P/E Ratio (0.000) is within average values for comparable stocks, (9.680). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.903). Dividend Yield (0.042) settles around the average of (0.048) among similar stocks. P/S Ratio (2.909) is also within normal values, averaging (4.418).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CURI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
a blank check company which, engages in effectuating a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Broadcasting
A.I.dvisor tells us that CURI and SALM have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CURI and SALM's prices will move in lockstep.
Ticker / NAME | Correlation To CURI | 1D Price Change % | ||
---|---|---|---|---|
CURI | 100% | +0.74% | ||
SALM - CURI | 23% Poorly correlated | +0.14% | ||
SSP - CURI | 22% Poorly correlated | -1.65% | ||
BBGI - CURI | 20% Poorly correlated | -3.49% | ||
CMLS - CURI | 20% Poorly correlated | +2.50% | ||
IHRT - CURI | 11% Poorly correlated | +0.66% | ||
More |